DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Completed · Phase 3 · NCT03529110
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $279,354
- U.S. investigators named
- 17
- Sites paid
- 15
- Planned or actual enrollment
- 524
About the trial
- Sponsor
- Daiichi Sankyo (with Daiichi Sankyo Co., Ltd., AstraZeneca)
- Tested
- Trastuzumab deruxtecan (T-DXd) (drug), Ado-trastuzumab emtansine (T-DM1) (drug)
- Dates
- Started 2018-08-09; completion 2026-08-31
- Results posted
- Yes
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
From ClinicalTrials.gov, last updated 2026-10-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $279,354 in research payments for this study in 2025 (203 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Omkar S. Marathe, MD Hematology & Oncology · Lakewood, CA
- Nicholas Mcandrew, M.D. Hematology & Oncology · Los Angeles, CA
- Christopher M. Gallagher, M.D. Hematology & Oncology · Washington, DC
- Fadi Kayali, M.D. Medical Oncology · Sarasota, FL
- Gail L. Wright, M.D. Medical Oncology · New Port Richey, FL
- Rajni Sinha, M.D. Hematology & Oncology · Atlanta, GA
- Charles L. Bane, MD Hematology & Oncology · Dayton, OH
- Alberto J. Montero, MD Hematology & Oncology · Cleveland, OH
- Nicole O. Williams, M.D. Medical Oncology · Columbus, OH
- Brooke E. Daniel, MD Hematology & Oncology · Chattanooga, TN
- Brent N. Rexer, MD, PHD Medical Oncology · Nashville, TN
- Barbara J. Haley, MD Hematology & Oncology · Dallas, TX
- Virginia Kaklamani, MD Medical Oncology · San Antonio, TX
- Polly Niravath, MD Internal Medicine · Houston, TX
- Namrata I. Peswani, M.D. Hematology & Oncology · Richardson, TX
- Charles L. Yen, M.D. Hematology & Oncology · Houston, TX
- Anuradha A. Belur, M.D Hematology & Oncology · Auburn, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute $100,743
- Ronald Reagan UCLA Medical Center, CA $76,829
- Medstar Health Research Institute $60,946
- University of Texas Health Science Center at San Antonio $9,217
- Uh Cleveland Medical Center, OH $9,079
- Vanderbilt University Medical Center, TN $6,370
- Waldron Medical Research and Development, Llc $4,883
- Deaconess Medical Center, WA $4,600
- The University of Texas Southwestern Medical Center at Dallas $1,835
- Piedmont Hospital, Inc, GA $1,779
- Ohio State University $864
- Premier Clinical Research $846
- Toi Clinical Research $695
- The Methodist Hospital Research Institute $573
- Medstar Research Institute $96
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.